TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Sponsor: Orca Biosystems, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT03802695 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03802695 Rescue Dossier →